Spots Global Cancer Trial Database for decitabine and cedazuridine
Every month we try and update this database with for decitabine and cedazuridine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes | NCT06091267 | Myelodysplastic... | IV Decitabine Decitabine and ... only Decitabine... | 18 Years - | Otsuka Beijing Research Institute | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | NCT04817241 | Acute Myeloid L... | Biospecimen Col... Bone Marrow Asp... Cytarabine Daunorubicin Decitabine and ... Venetoclax | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | NCT05037500 | Castration-Resi... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Decitabine and ... Enzalutamide | 18 Years - | Roswell Park Cancer Institute | |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | NCT05272384 | Recurrent B-Cel... Recurrent Diffu... Recurrent Hodgk... Refractory B-Ce... Refractory Diff... Refractory Hodg... | Biospecimen Col... Computed Tomogr... Decitabine and ... Nivolumab Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | NCT05456269 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Higher Risk Mye... Chronic Myelomo... | Bisantrene Dihy... Bisantrene Dihy... Cytarabine Hydr... Decitabine and ... | 18 Years - | Race Oncology Ltd | |
| BMS-986253 in Myelodysplastic Syndromes | NCT05148234 | Myelodysplastic... | decitabine and ... BMS-986253 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes | NCT06091267 | Myelodysplastic... | IV Decitabine Decitabine and ... only Decitabine... | 18 Years - | Otsuka Beijing Research Institute | |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | NCT04340843 | Locally Advance... Metastatic Prim... Unresectable Pr... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Decitabine and ... Guadecitabine Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT04774393 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Enasidenib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm | NCT05600894 | Chronic Myelomo... Myelodysplastic... Myelodysplastic... Myeloproliferat... | Biospecimen Col... Bone Marrow Bio... Decitabine and ... Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | NCT05456269 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Higher Risk Mye... Chronic Myelomo... | Bisantrene Dihy... Bisantrene Dihy... Cytarabine Hydr... Decitabine and ... | 18 Years - | Race Oncology Ltd | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | NCT05007873 | Chronic Phase C... Philadelphia Ch... BCR-ABL1 Positi... BCR-ABL1 Positi... | Dasatinib Decitabine and ... | - | M.D. Anderson Cancer Center | |
| PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes | NCT06091267 | Myelodysplastic... | IV Decitabine Decitabine and ... only Decitabine... | 18 Years - | Otsuka Beijing Research Institute | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | NCT04340843 | Locally Advance... Metastatic Prim... Unresectable Pr... | Belinostat Biopsy Biospecimen Col... Computed Tomogr... Decitabine and ... Guadecitabine Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NCT04975919 | Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... | Decitabine and ... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT05010122 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Refractory Acut... | Decitabine and ... Gilteritinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | NCT05673200 | Anatomic Stage ... Anatomic Stage ... Metastatic Trip... Unresectable Tr... | Biopsy Biospecimen Col... Computed Tomogr... Decitabine and ... Magnetic Resona... Paclitaxel Pembrolizumab | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
